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Remote monitoring of cardiac implantable 
electronic devices (CIEDs) affords an alternative 
to the one-on-one interaction required in tradi-
tional outpatient visits, and provides access to 
complete information on device performance [1]. 
The principal purposes of remote monitoring 
are: to reduce face-to-face hospital visits; ensure 
continuous follow-up and early detection of device 
malfunctions and subsequent clinical problems; 
and provide superior information processing [2]. 
On 31 December 2019, China reported 
a cluster of pneumonia cases with unknown etio-
logy to the World Health Organization (WHO), 
the causative pathogen later being identified as 
a novel coronavirus (SARS-CoV-2) [3]. On 11 March 
2020, WHO declared the pandemic phase of the 
outbreak [4].
On 20 February 2020, a male admitted to hos-
pital in Codogno (Lombardy, Italy) was confirmed 
as the first Italian citizen with COVID-19 [5–7]. 
The following day, a second outbreak was detected, 
in the Veneto region (Padua). The Government 
quarantined these two “red” areas by closing 
schools and commercial activities, and cancelling 
events. Our public hospital is located west of Vò 
Euganeo and east of Codogno; i.e., between the 
two outbreaks. 
COVID-19 patients at highest risk for more 
severe complications and death include people aged 
> 60 years and people with comorbidities. Mortal-
ity increases with age, with the highest rate among 
individuals over 80 years of age. Furthermore, 
mortality is higher among males compared with 
females. Patients with CIEDs followed by our clini-
cal center are of advanced age (mean age 78.5 ± 
± 10.6 years), with more than half (53.8%) 80 years 
of age or older (Table 1); most have cardiovascular 
disease; and there was a higher prevalence of men 
(62.7%; n = 570). Because the duration of this 
medical emergency was unknown and the above 
mentioned clinic population was largely at higher 
risk of serious consequences from COVID-19 
(Table 1), the aim was to check cardiac devices 
of patients using a home-monitoring system as 
much as was feasible, thereby reducing outpatient 
visits and decreasing infection risk for these fragile 
patients. While the Government was gradually 
extending restrictions outside of the two red ar-
eas, our unit quickly established a new procedure 
optimizing the management of CIED follow-ups. 
Overall, the remote monitoring system cov-
ered 909 CIEDs including 678 pacemakers (PMs), 
198 implantable cardioverter-defibrillators (ICDs) 
and 33 loop recorders. The following measures 
were introduced: first, patients previously refus-
ing device remote monitoring were contacted and 
strongly encouraged to accept this system. Should 
they accept, the telemonitoring system was dis-
patched and activated through a phone-mediated 
technical support system. Second, all devices 
without auto-thresholds (i.e., patients without PM-
-dependency) were exclusively checked through 
remote monitoring. Third, the new procedure 
required a mandatory attempt to solve all device 
alarms via phone communication. 
From 3 February to the day preceding the 
Italian outbreak, 40 patients had CIED monitor-
ing transmissions checked remotely (26 PMs and 
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14 ICDs), whereas 44 underwent checks face-to-
-face (Table 2). Among these face-to-face checks, 
17 were for clinical evaluation of the device pocket/ 
/wound after PM/ICD implantation/replacement, 
9 were electronic checks for devices unsuited 
to home monitoring, 4 were checks of remaining 
battery life, 4 were in patients who had previ-
ously refused home monitoring, 6 in patients with 
suspected device malfunctioning, and 4 for ICDs 
without an auto-threshold. In the same period, 
4 alerts were received: 2 in patients with new-onset 
atrial fibrillation (AF) and 2 in patients with abnor-
mal sensing of the ventricular lead. These patients 
were all managed through in-hospital consultations.
In an equivalent time frame following the 
COVID-19 outbreak, from 21 February (when the 
new procedure was activated) and up to 9 March, 
the total CIED transmissions checked remotely 
was 58 (40 PMs and 18 ICDs) and the number of 
face-to-face outpatient visits was 25, including 15 
clinical evaluations of the wound/pocket after de-
vice implantation/replacement and 10 checks of old 
PMs without a remote monitoring option (Table 2). 
In-office checks were avoided in 9 patients 
(5 received the remote monitoring device at home, 
4 had ICDs without an auto-threshold). During this 
period, 8 non-urgent alerts were received: 2 sinus 
pauses detected by loop recorders (these were 
already known about; no intervention needed), 
1 inappropriate shock (the patient was instructed by 
phone to increase their beta-blocker dose), 2 cases 
of a low percentage of biventricular stimulation in 
cardiac resynchronization devices (no interven-
tion required; these patients were already waiting 
for atrioventricular node ablation), 1 case of low 
sensing of the ventricular lead (we knew of this; 
the patient was in follow-up), and 2 new cases of 
AF. Among the 2 latter patients, one needed urgent 
evaluation for initiation of oral anticoagulation 
and the other, who had a dual-chamber PM and 
a history of recurrent episodes of AF, required 
pharmacotherapy modification; their prescription 
Table 1. Cardiovascular risk factors and comorbidities in the patients overall and comparison between 
the two samples evaluated between February 3rd and March 9th.
Overall patients with 
cardiac electronic  
devices (n = 909)
People evaluated from 
February 3rd to  
February 20th (n = 88)
People evaluated from 
February 21st to  
March 9th (n = 91)
P
Age [years] 78.5 ± 10.6 80.3 ± 13.2 79.4 ± 12.8 0.6
Age ≥ 80 year-old 489 (54%) 45 40 0.4
Males 570 (63%) 55 59 0.7
Hypertension 511 (56%) 48 54 0.5
Diabetes mellitus 68 (7%) 4 4 0.6
Dyslipidemia 288 (32%) 25 28 0.7
Coronary artery disease 212 (23%) 22 21 0.9
Dilatative cardiomyopathy 85 (9%) 10 12 0.8
Valvular disease 34 (4%) 3 1 0.4
Atrial fibrillation 373 (41%) 25 30 0.5
Chronic heart failure 139 (15%) 15 21 0.4
Chronic kidney disease* 177 (19%) 17 16 0.8
COPD 55 (6%) 3 5 0.7
*Glomerular filtration rate < 50 mL/min/m2; COPD — chronic obstructive pulmonary disease
Table 2. Patients with cardiac implantable electronic devices managed via face-to-face outpatient visits 
or remote monitoring during two equivalent time frames: before and after 20 February 2020 (Day 0 of 
the Italian COVID-19 outbreak).
Before Day 0 (n = 84) After Day 0 (n = 83) Difference, N (% change)
Outpatient visits 44 (52.4%) 25 (30.1%) –19 (–43.2%)
Remote monitoring 40 (47.6%) 58 (69.9%) +18 (+45.0%)
www.cardiologyjournal.org 337
Giacomo Mugnai et al., CIED remote monitoring during the Italian COVID-19 outbreak
was electronically sent to the pharmacy, avoiding 
travel to the hospital. Actually 5 out of 8 non-urgent 
alerts were “already-known” problems, therefore 
they were more easily managed through phone 
calls, thus avoiding in-office checks.
In summary, the application of the new pro-
cedure following the Italian COVID-19 outbreak 
resulted in a robust 43.2% decrease in the need for 
outpatient checks conducted face-to-face. Notably, 
all the alerts except one were managed through 
phone communication. At the same time, remote 
monitoring increased markedly, by 45%. 
Although comprising a small sample of patients 
and of short duration, this study demonstrates that 
a simple modified approach might be helpful for 
reducing in-office checks in patients with CIEDs, 
preserving the safety and efficiency of the whole 
monitoring system. This appears important in the 
current COVID-19 pandemic emergency, where 
reducing the number of new cases per unit of 
time is essential. Minimizing travel and hospital/ 
/outpatient clinic admissions for patients may mark- 
edly reduce the spread of COVID-19, especially 
if adopted by all hospitals for a prolonged dura-
tion, particularly those with high patient volumes. 
Furthermore, remote monitoring could be highly 
valuable for patient management and follow-up, 
in general. It reduces the number of face-to-face 
visits required — saving patients’ time and expense 
— and, thanks to continuous follow-up and early 
detection of device malfunctions, improves safety 
and quality of life.
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